US Federal Appeals Court Blocks Mail Delivery of Abortion Pills

A U.S. federal appeals court has issued a ruling prohibiting the mail delivery of the abortion pill mifepristone. The decision, which applies nationwide, found that the U.S. Food and Drug Administration (FDA) had acted improperly in its approval of mail delivery. This ruling suggests that conflicts between the federal government and state governments over regulatory authority for abortion could escalate.

Under the court's decision, women will now be required to see a healthcare professional in person to receive a prescription for mifepristone. This reverses changes that were relaxed during the COVID-19 pandemic. The appeals court's order blocks the mail distribution of mifepristone and effectively halts its direct dispensing by pharmacies, which was permitted under a recent FDA regulation change. The court mandated that the drug can only be dispensed through in-person consultations, adhering to previous safety protocols.

The court criticized the FDA for allegedly failing to adequately address the drug's safety data, deeming it 'unreasonable' to justify expanded access based on insufficient data after removing the requirement for reporting adverse events. This verdict marks a significant development in the legal battle over abortion pill regulation, as tensions are expected to intensify between federal regulatory bodies and states seeking to enforce stricter abortion laws.

The ruling upheld claims made by some pro-life states, such as Louisiana, supporting the argument that federal policy undermines state abortion laws. The court asserted that 'all abortions are void' under Louisiana's ban and that the state has the sovereign right to enact policies recognizing 'that every human life, from conception, is a human being.' According to research from the Guttmacher Institute, mifepristone is used in the majority of medication abortions performed in the U.S. Pro-life groups have welcomed the decision, calling it a 'long-awaited victory.'